I have been pitched investments in a doctors’ lounge, at a conference dinner, and twice in a specialty group chat. Every one of them came from another physician. That is not bad luck. That is the design.
This piece is about the specific ways physician money gets lost, and what actually works against each one. Not general advice about saving more. Named failure modes, with the fix for each. I have made a few of these myself, which is why I can describe them this precisely.
Most of it concerns private deals: the startup, the fund, the real estate syndication that reaches you through somebody you know. That is where physician money disappears fastest, and where almost nobody is measuring. Where I use public market research, it is because brokerage accounts are the only place scientists can actually watch investors behave. The behavior is the same in both.
The first problem is that we are a market. Conferences, newsletters, and entire sales teams exist to reach doctors, because we are a rare combination: high income, low free time, trained to trust credentials.
Real physician voices, twice a week
Free, and one click to unsubscribe.
The Securities and Exchange Commission (SEC) has a name for what gets built on top of that trust. Affinity fraud, which they define as investment scams that prey on members of an identifiable group, including professional groups.
Two cases show how it works. In 2020, the SEC charged a man who raised at least $33 million from about 150 investors for a crypto trading algorithm supposedly returning 15 percent a month. The account never held more than $6 million. The physicians who invested were brought in by a business partner who was himself a physician.
The second is uglier because of the detail. In 2015, a California man was sentenced to 57 months for defrauding 77 victims of more than $2 million. All 77 were medical professionals. One version promised returns on emerging medical technologies and took in 32 physicians. The other pitched dentists and orthodontists on a company developing a way to remove children’s wisdom teeth without surgery, and took in 45 more.
Read that again. The pitch was written in the language of our own expertise. The thing we know best was the way in, not the way out.
The fix is uncomfortable but simple. Shared identity is not diligence. When the person selling shares your degree, your specialty, or your alma mater, that fact should raise your standard, not lower it.
The second problem is believing that income protects us. It does not. The Financial Industry Regulatory Authority (FINRA) Investor Education Foundation asked 2,861 American investors last year whether they would put money into something promising a guaranteed, risk-free 25 percent return every year for five years. That is a textbook fraud signal. Half said they would invest.
Here is the number that should stop you. Between people earning under $50,000 and people earning over $100,000, the gap was 4 percentage points. Money does not buy resistance.
The fix is one rule you never bend. Guaranteed and high do not exist in the same sentence. Anything sold as both is either a lie or a misunderstanding, and you do not need to figure out which.
The third problem is assuming expertise travels. Being excellent at diagnosing disease does not make you good at reading a deal. Nobody claims otherwise out loud, but our behavior says we believe it.
The measured version is not flattering. Researchers gave 422 residents and fellows a 20-question personal finance test. The average score was 52 percent. A separate study found attendings beat residents overall and still averaged about 64 percent on retirement questions. Small studies at a few institutions, so hold them loosely.
The fix is to separate the two judgments out loud. You can be the best person in the room on whether a device works clinically and still be the worst person in the room on whether the company is priced correctly. Say which one you are answering.
The fourth problem is what happens when you have no time. Diligence gets skipped, and the deal that gets funded is whichever one arrived with the most social pressure attached. A colleague is in. The round closes Friday.
The fix is a default of no, and a floor you will not go under. If you cannot spend a serious block of hours on it, you are not investing, you are donating.
The last two problems come out of public market data, because that is where the account records live. They land harder in private deals, where positions cannot be sold at all.
The fifth problem is concentration, and the math here is brutal. In the largest study of retail investor accounts, covering 66,465 households, the median household held 2.61 stocks. A separate analysis of every U.S. stock since 1926 found four of every seven returned less than one-month Treasury bills over their lifetimes, and the best 4 percent of companies account for the entire net gain of the market.
So the market’s return lives inside a small handful of names. A three-position portfolio is not a strategy. It is a bet that you found one of them.
The fix is to hold more things than feels exciting. Boring diversification is the closest thing to a free lunch in this business.
The sixth problem is chasing the story while ignoring the friction. The same 66,465-household study found that the most active fifth of traders earned 11.4 percent a year against a market that returned 17.9 percent. Now the part almost everyone gets wrong. Those traders’ picks were fine. Their gross returns matched everyone else’s. Cost and frequency killed them, not the companies they chose.
Meanwhile, S&P’s scorecard through the end of 2025 found that over 20 years, 95 percent of U.S. stock funds underperformed their benchmark. Those are full-time professionals with research teams.
The fix is to treat fees, taxes, and turnover as the main event rather than the fine print. Over long periods, that is exactly what they are.
Now the counterexample, because physicians are not bad at this. We have a real edge when we use it.
I once looked at a surgical device company with clearance, real patents, thousands of units sold, and institutional investors already in at a $45 million valuation. On paper, it said yes. So I took it to five specialist surgeons separately and asked them to talk me out of it. All five landed in the same place. The clinical need was overstated, the real use was narrower than the pitch, and the operating room ecosystem the incumbents control was a wall. Then the arithmetic settled it. The kit ran about $700 against a Medicare payment near $300 for the procedure.
I passed in eleven days. That is not financial genius. That is five clinicians answering a clinical question honestly, which is a thing physicians can do that almost no investor can buy.
Which points at the actual lesson. The profession that proved a 19-item checklist could cut surgical deaths nearly in half, across eight hospitals on four continents, does not use a checklist before wiring money to a colleague’s deal.
We already know the answer here. We just have not applied it to our own money yet.
Harsha Moole is an internal medicine-trained physician-scientist with more than 100 peer-reviewed publications, including work featured in the New England Journal of Medicine. After years of clinical practice and gastroenterology outcomes research, he made an unconventional transition from the bedside to the boardroom by founding PhysicianEstate, a health care-focused venture capital firm.
Over the past seven years, Dr. Moole has made 22 early-stage health care investments across digital health, medical devices, biotech, and therapeutics. He has also built a network of more than 200 physicians from institutions such as Johns Hopkins and Stanford who help source opportunities and provide clinical diligence before capital is deployed. His core thesis is that physician-scientists with firsthand clinical experience are uniquely positioned to identify health care investments that generalist investors often miss.
His research background is reflected in his publication record on Google Scholar, and he shares professional updates on LinkedIn.
